A number of research firms have changed their ratings and price targets for Fortuna Mining (NYSE: FSM): 12/23/2025 – Fortuna Mining was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating. 12/15/2025 – Fortuna Mining had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings. 12/15/2025 – Fortuna […]

A number of research firms have changed their ratings and price targets for Marriott Vacations Worldwide (NYSE: VAC): 12/21/2025 – Marriott Vacations Worldwide was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating. 12/15/2025 – Marriott Vacations Worldwide had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings. […]

Several brokerages have updated their recommendations and price targets on shares of Equitable (NYSE: EQH) in the last few weeks: 12/17/2025 – Equitable had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. 12/15/2025 – Equitable is now covered by analysts at Mizuho. They set an “outperform” rating and a $66.00 price target on […]

Domo (NASDAQ: DOMO) recently received a number of ratings updates from brokerages and research firms: 12/21/2025 – Domo was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating. 12/13/2025 – Domo was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating. 12/5/2025 – […]

A number of firms have modified their ratings and price targets on shares of Lexaria Bioscience (NASDAQ: LEXX) recently: 12/15/2025 – Lexaria Bioscience had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings. 12/8/2025 – Lexaria Bioscience had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings. 12/7/2025 – Lexaria Bioscience was downgraded […]

Acadia Healthcare (NASDAQ: ACHC) has recently received a number of price target changes and ratings updates: 12/18/2025 – Acadia Healthcare had its price target lowered by analysts at Mizuho from $22.00 to $17.00. They now have a “neutral” rating on the stock. 12/4/2025 – Acadia Healthcare had its price target lowered by analysts at Barclays […]

Supernus Pharmaceuticals (NASDAQ: SUPN) recently received a number of ratings updates from brokerages and research firms: 12/19/2025 – Supernus Pharmaceuticals had its price target raised by analysts at Stifel Nicolaus from $50.00 to $55.00. They now have a “hold” rating on the stock. 12/15/2025 – Supernus Pharmaceuticals had its “sell (d+)” rating reaffirmed by analysts […]

A number of research firms have changed their ratings and price targets for Acrivon Therapeutics (NASDAQ: ACRV): 12/22/2025 – Acrivon Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings. 12/21/2025 – Acrivon Therapeutics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating. 12/15/2025 – Acrivon […]